RVNC - Revance Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.86
-0.11 (-1.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.97
Open10.94
Bid10.03 x 1000
Ask14.15 x 800
Day's Range10.69 - 11.15
52 Week Range10.37 - 31.65
Volume853,084
Avg. Volume344,590
Market Cap477.912M
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire10 days ago

    Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Jill Beraud to the company’s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand Strategy Committee focused on establishing the company’s innovative neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in the minds of consumers.

  • Business Wire12 days ago

    Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

  • Business Wirelast month

    Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions.

  • Business Wirelast month

    Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update

    - Conference call and webcast today at 4:30 p.m. ET -

  • Business Wire2 months ago

    Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release first quarter 2018 financial results on Wednesday, May 8, 2019 after the close of market. DAXI has the potential to be the first long-acting neuromodulator.

  • Business Wire2 months ago

    Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of Taryn Conway as Vice President, Marketing, effective April 8, 2019. As the company transitions from clinical-stage development to commercialization, Ms. Conway will be an integral architect of product launch strategies and implementation, reporting to Head of Commercial - Aesthetics and Therapeutics, Dustin Sjuts. “We’re thrilled that Taryn will be leading our marketing efforts as we approach the anticipated launch of our first-in-class, long-lasting neuromodulator, DaxibotulinumtoxinA for Injection (DAXI),” said Dustin Sjuts, Head of Commercial - Aesthetics and Therapeutics, for Revance.

  • Business Wire2 months ago

    SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference

    – Unprecedented clinical results for DaxibotulinumtoxinA for Injection , Revance’s long-acting neuromodulator, were highlighted at the 17th Aesthetics & Anti-Aging Medica

  • Business Wire2 months ago

    Revance to Participate in the Needham Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York, NY. Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, April 9 at 12:00pm ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Revance to Participate in Upcoming Investor Conferences

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

  • Business Wire4 months ago

    Revance Releases Fourth Quarter and Full Year 2018 Results

    -Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed-

  • Business Wire4 months ago

    Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

    Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET

  • GlobeNewswire4 months ago

    CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and to the Board’s Audit Committee. “Dr. Gardner’s very broad and deep expertise in medicine, biotechnology, and corporate investing and governance is an ideal skill set for the CohBar Board as we strategically advance our portfolio and pipeline of mitochondrial peptides and disease targets,” said Albion Fitzgerald, Chairman of the Board.

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire5 months ago

    Revance Announces Closing of Public Offering of Common Stock

    Gross Proceeds of Offering Total 115.0 Million

  • Business Wire5 months ago

    Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of additional 882,352 shares from the Company. The gross proceeds to the Company from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $100 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • Business Wire5 months ago

    Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock. Revance expects that the underwriters will be granted a 30-day option to purchase from the Company up to an additional 15% of the shares of its common stock. The Company intends to use the net proceeds received from its offering of common stock for working capital and general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments.

  • Business Wire5 months ago

    Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference

    - Revance’s long-acting neuromodulator RT002, along with its unique proprietary peptide and formulation technology, will be featured in 11 podium and poster presentations at the TO

  • Business Wire5 months ago

    Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones

    “Revance is entering 2019 with tremendous momentum on multiple fronts,” said Dan Browne, president and chief executive officer at Revance. “We have an exciting ensemble of late-stage clinical trials underway for our next-generation neuromodulator and are operating a U.S.-based, commercial-scale drug substance and drug product facility to manufacture a broad range of proprietary neuromodulation formulations.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and Revance Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 5, 2018 / Shares of Novelion Therapeutics and Revance Therapeutics were both soaring on Tuesday on separate developments. Novelion saw gains as it was revealed that biotech focused venture capital firm Healthcare Value Capital sent a letter demanding exploration of strategic alternatives, while Revance Therapeutics soared on news that its Botox rival succeeds in late-stage trial and that it had reached an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Novelion Therapeutics Inc. shares were up 32.65% yesterday at the close on almost 17.5 million shares traded.

  • Business Wire6 months ago

    Revance Announces China Market License Agreement with Fosun Pharma for RT002

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize Revance’s proprietary DaxibotulinumtoxinA for Injection (RT002) in mainland China, Hong Kong and Macau (the Territory). RT002 is a novel, long-lasting neuromodulator in development for the treatment of aesthetic conditions, including glabellar and upper facial lines, and neuroscience conditions including cervical dystonia, plantar fasciitis, adult upper limb spasticity and chronic migraine.

  • Business Wire6 months ago

    Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate-to-severe glabellar (frown) lines in the SAKURA 3 Phase 3 open-label, long-term safety study. As a component of the largest clinical program of an aesthetic neuromodulator, the SAKURA 3 study included nearly 2,700 patients and more than 3,800 treatments.

  • GlobeNewswire7 months ago

    Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire7 months ago

    Revance to Participate in the Credit Suisse Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare Conference in Phoenix, AZ.